The information in the graphic above was pulled from a New York Times review of the Mounjaro Phase III clinical trial information
Moreover, Important context: As of July 2026, eloralintide, cagrilintide, and petrelintide remain research-stage as standalone weight-management medicines
Concurrently, a reduction in the abundance of commensal bacteria capable of producing beneficial metabolites, such as short-chain fatty acids (SCFAs), diminishes their protective effects on the host, effectively transforming the gut microbiota from a symbiotic partner into a potent risk modulator for cardiovascular disease 11,12,13
Sinomenine (SIN) can alleviate the symptoms of CIA by targeting Lactobacillus and microbial tryptophan metabolites to activate the aryl hydrocarbon receptor (AhR) and modulate the Th17/Treg balance (Jiang et al., 2023